Raymond James & Associates
MYOK

Raymond James & Associates’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Raymond James & Associates’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,984
Closed -$1.91M – 3950
2020
Q3 		$1.91M Buy
13,984
+3,659
+35% +$389K ﹤0.01% 1793
2020
Q2 		$998K Buy
10,325
+819
+9% +$68.3K ﹤0.01% 2165
2020
Q1 		$446K Sell
9,506
-897
-9% -$57.5K ﹤0.01% 2494
2019
Q4 		$758K Buy
10,403
+1,794
+21% +$109K ﹤0.01% 2448
2019
Q3 		$449K Buy
8,609
+1,686
+24% +$89.7K ﹤0.01% 2722
2019
Q2 		$347K Buy
6,923
+742
+12% +$36.1K ﹤0.01% 2915
2019
Q1 		$321K Buy
+6,181
New +$285K ﹤0.01% 2941

Raymond James & Associates's MYOK Position: Q4 2020 in Review

Raymond James & Associates sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 13,984 shares — an estimated $1.91M sold.

Raymond James & Associates first reported a position in MYOK in Q1 2019 and held it in 7 quarters. The position peaked at $1.91M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.

  • Raymond James & Associates reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 13,984 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $1.91M.
  • Raymond James & Associates first reported a position in MyoKardia, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
  • Raymond James & Associates's MyoKardia, Inc. Common Stock position peaked at $1.91M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.